Skip to content

close

About Yuhan

homeHOME About Yuhan History

History

prev

2010~ now

2010~ now

2010~ now

2010~ now

next

2010~ now

  • 2025

    • Korea's most respected pharmaceutical Company
      All-star and No.1 Pharmaceutical sector for 22 consecutive years
    • Yuhan Corporation Achieves KRW 2.0677 Trillion in Sales in 2024

  • 2024

    • Korea's most respected pharmaceutical Company
      All-star and No.1 Pharmaceutical sector for 21 consecutive years
    • Yuhan Corporation Achieves KRW 1.8589 Trillion in Sales in 2023
    • 2024 Korea Sustainability Index (KSI) – Ranked No.1 in the Pharmaceutical Sector
    • 31st Corporate Innovation Awards – Presidential Commendation

  • 2023

    • Korea's most respected pharmaceutical Company
      All-star and No.1 Pharmaceutical sector for 20 consecutive years
    • Yuhan Corporation Achieves KRW 1.7758 Trillion in Sales in 2022
    • 2023 Love Sharing Social Contribution Award – Minister of Health and Welfare Commendation (ESG Management Category)
    • Model Export Company for Childbirth and Parenting – Business Growth Achievement Category of Minister of Trade, Industry and Energy Commendation

  • 2022

    • Korea's most respected pharmaceutical Company
      All-star and No.1 Pharmaceutical sector for 19 consecutive years
    • Yuhan Corporation Achieves KRW 1.6787 Trillion in Sales in 2021
    • Recognized as an Excellent Public Disclosure Company
    • 2022 Gender Equality in Employment Excellence Award – Prime Minister’s Commendation
    • Awarded as an Outstanding Innovative Pharmaceutical Company
    • Korea ESG Company of the Year – Grand Prize in Bio & Healthcare Sector

  • 2021

    • Innovative New Drug for Lung Cancer, Leclazar Tablet, Secures Insurance Reimbursement
    • Innovative New Drug for Lung Cancer, Leclazar Tablet, Granted Conditional Product Approval
    • Korea's most respected pharmaceutical Company
      All-star and No.1 Pharmaceutical sector for 18 consecutive years
    • Yuhan Corporation Achieves KRW 1.6198 Trillion in Sales in 2020
    • Certified Family-Friendly Company
    • Selected as the Top Company for Social Value at the Korea Management Awards
    • 2021 Korea Bio-Health Grand Prize – Winner in the New Drug Category

  • 2020

    • Yuhan Corporation is recognized as the most respected company in Korea by the Korean Management Association
    • All Star 17 (first in Pharmaceuticals) 17 consecutive years
    • Yuhan Corporation, 2019 Revenue 1.4804 trillion won

  • 2019

    • Yuhan Corporation is recognized as the most respected company in Korea by the Korean Management Association
    • All Star 16 (first in Pharmaceuticals) 16 consecutive years
    • Yuhan Corporation, 2018 Revenue 1.5188 trillion won (#1 in the industry)

  • 2018

    • Yuhan Corporation is recognized as the most respected company in Korea by the Korean Management Association
    • All Star 15 (first in Pharmaceuticals) 15 consecutive years
    • Yuhan Corporation, 2017 Revenue 1.4622 trillion won (#1 in the industry)

  • 2017

    • Received Korean Government’s ($200 million USD) Export Tower Award
    • Received 2017 The 41st National Productivity Award from Korean President
    • New Il-Han Award (Prof. Kim. H. S. Yonsei Univ)

  • 2016

    • The ninety(90) years of company establishment
    • All Star 13 (first in Pharmaceuticals) 13 consecutive years

  • 2015

    • All Star 12 (first in Pharmaceuticals) 12 consecutive years

  • 2014

    • All Star 11 (first in Pharmaceuticals) 11 consecutive years

  • 2013

    • Yuhan Corporation is recognized as the most respected company in Korea by the Korean Management Association
    • Received Korean government’s ($100 million USD) Export Tower Award
    • First in Korean pharmaceutical industry to receive 10th No-Accident certificate

  • 2012

    • Established strategic alliance with HanAll Biopharma Co., Ltd., of Seoul, Korea
    • Received Innovative Pharmaceutical Enterprise certification from the Korean Ministry of Health and Welfare

  • 2011

    • Cooperative development contract with Esoltek investment for degenerative arthritis medication

  • 2010

    • Revanex Out-Licensing to China
    • Ochang plant received KOSHA 18001/OHAS 18001 certification
    • Received 2010 Labor and Culture Award from Korean Prime Minister